诺华
诺华是一家全球领先的创新药物公司。我们的使命是创想医药未来，改善人们生活质量，延长人类寿命。2023年，全球有约2.84亿患者受益于诺华的产品。
秉持“承诺中华”的理念，诺华从研发、生产到业务发展，全面布局中国市场。
我们致力于为中国患者提供高临床价值的创新药。自1987年以来，诺华已有超过100款创新药物及新适应症在华获批。
通过深化与中国医疗生态系统各方的多方位合作，诺华不断助力提升疾病诊疗标准，积极履行企业责任，推动健康中国战略的实施，从而为中国发展做出切实而积极的贡献。我们运用创新科学和数字化技术，在具有重大医药健康需求的领域创造变革性的治疗方法。在探索新药的过程中，我们不懈创新，研发投入一直处于全球行业先列。
Novartis is a leading global innovative medicines company with a vital purpose to reimagine medicine to improve and extend people's lives. Novartis medicines reached around 284million patients globally in 2023.
With a long-term commitment to China, we have established an integrated presence from R&D, manufacturing and commercial operations.
We are committed to providing high-value innovative medicines in China, obtaining more than 100 approvals for new drugs and indications since 1987.
By strengthening partnerships with multiple healthcare ecosystem stakeholders,we are making impactful contributions to improve the standard of care in China, fulfill corporate responsibility, and help achieve national healthcare priorities.